Natalia Martínez, Teresa Gragera, María Pilar de Lucas, Ana Belén Cámara, Alicia Ballester, Berta Anta, Alberto Fernández-Medarde, Tania López-Briones, Judith Ortega, Daniel Peña-Jiménez, Antonio Barbáchano, Ana Montero-Calle, Víctor Cordero, Rodrigo Barderas, Teresa Iglesias, Mónica Yunta, José Luís Oliva, Alberto Muñoz, Eugenio Santos, Natasha Zarich, José M Rojas-Cabañeros
Spry2 is a molecular modulator of tyrosine kinase receptor signaling pathways that has cancer-type-specific effects. Mammalian Spry2 protein undergoes tyrosine and serine phosphorylation in response to growth factor stimulation. Spry2 expression is distinctly altered in various cancer types. Inhibition of the proteasome functionality results in reduced intracellular Spry2 degradation. Using in vitro and in vivo assays, we show that protein kinase D (PKD) phosphorylates Spry2 at serine 112 and interacts in vivo with the C-terminal half of this protein...
April 12, 2023: Oncogenesis